Research programme: hepatitis B vaccine - Chongqing Zhifei Biological Products
Latest Information Update: 16 Jul 2016
At a glance
- Originator Chongqing Zhifei Biological Products
- Class Hepatitis B vaccines
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-B in China
- 02 Apr 2013 Preclinical trials in Hepatitis B in China (unspecified route)